Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End
Kazia Therapeutics Regains Full Nasdaq Listing Compliance [Yahoo! Finance]
Kazia Therapeutics Regains Full Nasdaq Listing Compliance
Novogen (NASDAQ:KZIA) had its price target raised by analysts at HC Wainwright from $13.00 to $18.00. They now have a "buy" rating on the stock.
Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+